ResearcherWenzhou Medical UniversityNo recent work listed

Shihui Bao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0000-2395-7698; OpenAlex author ID A5115591845. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2021: 2 papers

Papers 2

ATB0,+-targeted delivery of triptolide prodrugs for safer and more effective pancreatic cancer therapy. Last author DOI 10.1016/j.bmcl.2020.127728 ↗
Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treatment. Co-author DOI 10.3389/fphar.2021.625084 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Ruijie Chen · 2 shared papers, 2021 · strength 0.25
- Paper Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treat… DOI 10.3389/fphar.2021.625084 ↗
- Paper ATB0,+-targeted delivery of triptolide prodrugs for safer and more effective pancreatic cancer therapy. DOI 10.1016/j.bmcl.2020.127728 ↗
Longfa Kou · 2 shared papers, 2021 · strength 0.25
- Paper Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treat… DOI 10.3389/fphar.2021.625084 ↗
- Paper ATB0,+-targeted delivery of triptolide prodrugs for safer and more effective pancreatic cancer therapy. DOI 10.1016/j.bmcl.2020.127728 ↗
Hailun Zheng · 1 shared paper, 2021 · strength 0.13
- Paper Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treat… DOI 10.3389/fphar.2021.625084 ↗
Dan Wen Lou · 1 shared paper, 2021 · strength 0.12
- Paper ATB0,+-targeted delivery of triptolide prodrugs for safer and more effective pancreatic cancer therapy. DOI 10.1016/j.bmcl.2020.127728 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.